Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study

Autor: Kiladjian, Jean-Jacques *, Zachee, Pierre, Hino, Masayuki, Pane, Fabrizio, Masszi, Tamas, Harrison, Claire N, Mesa, Ruben, Miller, Carole B, Passamonti, Francesco, Durrant, Simon, Griesshammer, Martin, Kirito, Keita, Besses, Carlos, Moiraghi, Beatriz, Rumi, Elisa, Rosti, Vittorio, Blau, Igor Wolfgang, Francillard, Nathalie, Dong, Tuochuan, Wroclawska, Monika, Vannucchi, Alessandro M, Verstovsek, Srdan
Zdroj: In The Lancet Haematology March 2020 7(3):e226-e237
Databáze: ScienceDirect